Ethanolic extracts of Brassica campestris spp. rapa roots prevent high-fat diet-induced obesity via beta(3)-adrenergic regulation of white adipocyte lipolytic activity.
The influence of ethanolic extracts of Brassica campestris spp. rapa roots (EBR) on obesity was examined in imprinting control region (ICR) mice fed a high-fat diet (HFD) and in 3T3-L1 adipocytes. The ICR mice used were divided into regular diet, HFD, EBR (50 mg/kg/day EBR administered orally), and orlistat (10 mg/kg/day orlistat administered orally) groups. The molecular mechanism of the anti-obesity effect of EBR was investigated in 3T3-L1 adipocytes as well as in HFD-fed ICR mice. In the obese mouse model, both weight gain and epididymal fat accumulation were highly suppressed by the daily oral administration of 50 mg/kg EBR for 8 weeks, whereas the overall amount of food intake was not affected. EBR treatment induced the expression in white adipocytes of lipolysis-related genes, including beta(3)-adrenergic receptor (beta(3)-AR), hormone-sensitive lipase (HSL), adipose triglyceride lipase, and uncoupling protein 2. Furthermore, the activation of cyclic AMP-dependent protein kinase, HSL, and extracellular signal-regulated kinase was induced in EBR-treated 3T3-L1 cells. The lipolytic effect of EBR involved beta(3)-AR modulation, as inferred from the inhibition by the beta(3)-AR antagonist propranolol. These results suggest that EBR may have potential as a safe and effective anti-obesity agent via the inhibition of adipocyte lipid accumulation and the stimulation of beta(3)-AR-dependent lipolysis.
An
Sojin
S
National Research Laboratory of Lipid Metabolism & Atherosclerosis, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Han
Jang-Il
JI
Kim
Min-Jung
MJ
Park
Ji-Seon
JS
Han
Jong-Min
JM
Baek
Nam-In
NI
Chung
Hae-Gon
HG
Choi
Myung-Sook
MS
Lee
Kyung-Tae
KT
Jeong
Tae-Sook
TS
D052438:Adipocytes, White / Q000378:metabolism*; D018663:Adrenergic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001937:Brassica; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D004041:Dietary Fats / Q000008:administration & dosage; D004195:Disease Models, Animal; D002149:Energy Intake; D004789:Enzyme Activation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D007473:Ion Channels / Q000378:metabolism; D008049:Lipase / Q000378:metabolism; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D024101:Mitochondrial Proteins / Q000378:metabolism; D009765:Obesity / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D018517:Plant Roots; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000378:metabolism; D002787:Sterol Esterase / Q000378:metabolism; D000071246:Uncoupling Protein 2; D015430:Weight Gain / Q000187:drug effects
D018663:Adrenergic Agents; D019440:Anti-Obesity Agents; D004041:Dietary Fats; D007473:Ion Channels; D024101:Mitochondrial Proteins; D010936:Plant Extracts; D011941:Receptors, Adrenergic; C000604390:Ucp2 protein, mouse; D000071246:Uncoupling Protein 2; D011433:Propranolol; D017868:Cyclic AMP-Dependent Protein Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D002787:Sterol Esterase; D008049:Lipase